Life Sciences in 2026: Operating with Confidence in an Era of Regulation, Complexity and Resilience

In the United States, scale, innovation funding and rapid adoption of advanced therapies continue to support growth. However, pricing reform, reimbursement scrutiny and policy intervention are intensifying. The Inflation Reduction Act has made operational and lifecycle decisions inseparable from commercial strategy.

Across Europe, fragmented access regimes, joint clinical assessments and cost-containment pressures are raising the bar for evidence, compliance and operational discipline. For many organizations, operational confidence is becoming as critical as innovation.

Regulation has moved from a downstream checkpoint to a core driver of strategic and operational decisions. Manufacturing footprint, network design, partner selection and scale-up pathways are increasingly shaped by regulatory exposure and policy risk.

Crucially, regulatory requirements continue to evolve while products are already in development or on the market. The challenge has shifted from how to comply to how to design operating systems that remain robust while the rules continue to move.

Scientific progress is accelerating complexity. Advanced therapies, broader portfolios and specialized processes are reducing effective capacity and increasing cost, even where headline capacity appears sufficient.

In many organizations, cost pressure is no longer driven primarily by inefficiency. It is driven by upstream design choices in portfolio strategy, network architecture and operating-model decisions.

Recent years have exposed structural vulnerabilities across global life sciences supply chains. Regulators, healthcare systems and patients now expect continuity of supply as a baseline requirement.

Resilience is often misunderstood. Inventory and duplication alone add cost without addressing root causes. Well-designed resilience improves reliability, responsiveness and trust—and increasingly differentiates leaders from laggards.

Regulation increases complexity. Complexity erodes flexibility. Reduced flexibility weakens resilience. Treating these as isolated initiatives guarantees sub-optimal outcomes.

What is required is a system-level response, joined-up decisions across strategy, operations, supply chain, quality, digital and organization.

Publicly visible decisions by leading pharmaceutical companies over the past three years show a decisive shift away from generic global scale toward modality-specific, regionally resilient operating models.

Leaders are selectively regionalizing strategic capacity, designing networks around modality physics, pulling critical bottlenecks inside and treating operations as a growth and launch-reliability lever rather than a back-office function.

Leading organizations are becoming more deliberate about what must be local, what must be specialized and what can remain flexible. These choices are increasingly supported by stronger digital orchestration, governance and decision rights.

At EFESO, we see life sciences leaders moving away from isolated transformation programmes toward integrated, system-level redesign of operations and supply chains.

With deep expertise across manufacturing, supply chain, procurement and operations strategy, EFESO supports clients in navigating complexity by simplifying, aligning and strengthening the system as a whole.

The challenge for 2026 is not to solve regulation, complexity or resilience in isolation. It is to recognize that they are now one interconnected problem.

Organizations that address them together will unlock faster decision-making, greater resilience and more sustainable performance. The question is no longer whether to act, but how quickly can systems be redesigned to keep up.

Download the full whitepaper to learn how to operate with confidence and resilience.